First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
Rom S LeidnerKevin C ConlonDouglas G McNeelAndrea Wang-GillamSumati V GuptaRobert WesolowskiMonica ChaudhariNadia HassounahJong Bong LeeLang Ho LeeJessica A O'KeeffeNancy LewisGeorge N PavlakisJohn A ThompsonPublished in: Journal for immunotherapy of cancer (2023)
NCT02452268.
Keyphrases